9 results match your criteria: "Saint Louis Veterans Administration Medical Center[Affiliation]"
Venous thromboembolism and mortality in patients with hematological malignancies.
Bleeding Thromb Vasc Biol
May 2024
Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Mortality and venous thromboembolism (VTE) are major risks for patients with hematological malignancies. However, they are commonly underrepresented in major clinical trials of VTE. Treatment decisions are further complicated by the unique characteristics they frequently exhibit, such as thrombocytopenia.
View Article and Find Full Text PDFDOAC compared with warfarin for VTE in low weight patients: A retrospective cohort study conducted through the VENUS network.
Thromb Res
September 2023
Department of Medicine, Division of Hematology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America.
Correction to: DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network.
J Thromb Thrombolysis
May 2023
Division of Hematology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network.
J Thromb Thrombolysis
May 2023
Division of Hematology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
The effectiveness and safety of direct oral anticoagulants (DOAC) compared with warfarin remains uncertain in obese patients. We assessed the comparative effectiveness and safety of DOACs with warfarin for the treatment of VTE among obese patients. This multi-center retrospective cohort study included adults with a BMI ≥ 35 kg/m or weight ≥ 120 kg prescribed either DOAC (apixaban, dabigatran, edoxaban, rivaroxaban) or warfarin for a VTE diagnosis.
View Article and Find Full Text PDFThrombosis and bleeding in hematological malignancy.
Best Pract Res Clin Haematol
March 2022
Department of Medicine, Washington University St. Louis School of Medicine, Saint Louis, Missouri, USA; Department of Medicine, Saint Louis Veterans Administration Medical Center, Saint Louis, Missouri, USA. Electronic address:
Venous (VTE) and arterial (ATE) thromboemboli are a leading cause of morbidity and mortality in patients with cancer. Patients with hematological malignancies are at an exceptionally high risk of both VTE and ATE. This risk varies based on patient- and disease-specific risk factors and can be predicted using risk prediction models for some types of hematological malignancies.
View Article and Find Full Text PDFStandardization of risk prediction model reporting in cancer-associated thrombosis: Communication from the ISTH SSC subcommittee on hemostasis and malignancy.
J Thromb Haemost
August 2022
Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
Since the development of the Khorana score to predict risk of cancer-associated venous thromboembolism (VTE), many modified and de novo risk prediction models (RPMs) have been proposed. Comparison of the prognostic performance across models requires comprehensive reporting and standardized methods for model development, validation and evaluation. To improve the standardization of RPM reporting, the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD) tool was published in 2015.
View Article and Find Full Text PDFHuman pegivirus (GB virus C) NS3 protease activity inhibits induction of the type I interferon response and is not inhibited by HCV NS3 protease inhibitors.
Virology
May 2014
Saint Louis University School of Medicine, Department of Molecular Microbiology and Immunology, St. Louis, MO, USA; Saint Louis University School of Medicine, Department of Internal Medicine, Division of Infectious Diseases, Allergy & Immunology, St. Louis, MO, USA; Saint Louis Veterans Administration Medical Center, St. Louis, MO, USA. Electronic address:
Article Synopsis
- HPgV NS3 protease has been found to inhibit HIV replication in CD4+ T cells while also being similar to the HCV NS3 protease.
- Researchers investigated whether HPgV protease affects type I interferon responses or is impacted by HCV protease inhibitors and found that major HCV inhibitors do not affect HPgV activity.
- The study revealed that HPgV NS3 protease can cleave MAVS and inhibit interferon responses, potentially promoting HPgV persistence, which may provide clinical benefits for HIV-infected patients.
Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: correlation with serum and local antibodies.
J Am Geriatr Soc
February 1992
Gerontology Research Education and Clinical Center, Saint Louis Veterans Administration Medical Center, Missouri.
Objective: To compare young and elderly adults in terms of their immune responses and rates of infection following intranasal vaccination with a live attenuated influenza virus.
Design: Time series, comparing outcomes in young and elderly convenience sample.
Method: Retrospective laboratory analysis of serum and nasal wash specimens collected during prior studies in which young or elderly volunteers had been inoculated with cold-adapted influenza A/Kawasaki/86 (H1N1) reassortant virus.
Neurophysiologic evaluation of patients with low back pain.
Semin Neurol
December 1986
Spinal Cord Injury Service, Saint Louis Veterans Administration Medical Center, MO 63125.
1. Neurophysiologic testing is as accurate as CT scanning or myelography in the diagnosis of root compression due to disk disease. 2.
View Article and Find Full Text PDF